Ultragenyx Announces Phase 3 Aspire Results In Angelman Syndrome
RARE•Phase 3 Aspire results in Angelman syndrome
Sept. 2 (Reuters) - Ultragenyx Pharmaceutical Inc. (RARE.O):
- Ultragenyx announces Phase 3 Aspire results in Angelman syndrome.
- The Phase 3 Aspire study did not achieve primary or key secondary endpoints.
- Safety profile in the Aspire study was consistent with Phase 1/2.
- Ultragenyx will evaluate the apazunersen program and implement significant expense reductions.
- The company expects to continue toward profitability in 2027.
Source text: ID:nGNX5gyGjV
Further company coverage: RARE.O
